drugset / Trial / NCT00379977

Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age

NCT00379977

Phase 3 Completed 30 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelPrevention

Summary

This study will evaluate the safety and reactogenicity of GSK Biologicals' Diphtheria Tetanus acellular Pertussis/Haemophilus influenzae type b vaccine given to Chinese infants at 3, 4 and 5 months of age.

Timeline

Start
2006-09
Primary completion
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Hepatitis B Vaccine